New vaccine combo shows promise in fight against deadly brain tumors

NCT ID NCT07347210

First seen Jan 19, 2026 · Last updated May 14, 2026 · Updated 19 times

Summary

This study tests whether adding a cancer vaccine (UCPVax), with or without an immunotherapy drug (pembrolizumab), to standard treatment can help people with a fast-growing type of brain cancer (glioblastoma) live longer. About 98 adults with newly diagnosed glioblastoma that has a specific genetic marker (unmethylated MGMT) will take part. The goal is to see if these added treatments improve survival at 18 months compared to standard care alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU La Timone

    Marseille, France

    Contact

    Contact

  • CHU de Besançon

    Besançon, France

    Contact

    Contact

  • Centre Georges François Leclerc

    Dijon, France

    Contact

    Contact

  • Hôpital Saint-Louis - APHP

    Paris, France

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.